ORTX News and Press, Orchard Therapeutics plc From 10/05/23

2023-10-05 10:00:20 ET More on Health Care Select Sector SPDR BofA Securities: Which small cap non-earner stocks to avoid Citi turns cautious on pharmaceuticals and biotech For further details see: Orchard Therapeutics, Longeveron among healthcare movers

Shares of Orchard Therapeutics PLC (NASDAQ: ORTX) traded at a new 52-week high today and are currently trading at $15.94. So far today, approximately 5.04M shares have been exchanged, as compared to an average 30-day volume of 101.26k shares. Orchard Therapeutics PLC, a biopharmaceutical comp...

2023-10-05 08:54:18 ET Orchard Therapeutics ( NASDAQ: ORTX ) +97% . Grom Social Enterprises  ( GROM ) +29% . Janover  ( JNVR ) +19% Drives Lender Growth on its Fintech Marketplace. Femasys  ( FEMY ) +18% Femasys Inc. to ...

2023-10-05 05:48:00 ET NASDAQ: RIVN plunged more than 9% Related stories BlackBerry Limited (BB) Q2 2024 Earnings Call Transcript Does Rivian Still Have An Existential Crisis? BlackBerry Earnings Preview: Pre-Announcement May Not Save Further Sell-Off ...

2023-10-05 05:24:47 ET More on both companies Orchard Therapeutics: A Reassessment Orchard Therapeutics: Highly Valued Once, Undervalued Today Orchard Therapeutics stock jumps 13% as FDA accepts BLA for OTL-200 For further details see: Kyowa Kirin to buy ...

-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases- -Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated plat...

2023-09-20 07:52:00 ET More on Orchard Therapeutics Seeking Alpha’s Quant Rating on Orchard Therapeutics Historical earnings data for Orchard Therapeutics Financial information for Orchard Therapeutics Orchard Therapeutics: A Reassessment Orcha...

2023-09-18 15:13:48 ET Orchard Therapeutics ( NASDAQ: ORTX ) stock jumped 13% in afternoon trading Monday after the company said that its Biologics License Application for its drug OTL-200 had been accepted by the FDA under its priority review program, with a decision expected by Ma...

2023-09-18 09:20:41 ET Summary Orchard Therapeutics plc is a London-based biotech company focused on developing gene therapies for rare diseases. The company's lead therapy, OTL-200, has received marketing authorization in Europe for the treatment of metachromatic leukodystrophy. ...

PDUFA date set for March 18, 2024 OTL-200 would be the first and only treatment in the U.S. for early-onset MLD Previously published data demonstrated administration of one-time gene therapy enables sustained preservation of motor function and cognitive development BOSTON ...